SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories launches Pemetrexed for injection in US market

30 May 2022 Evaluate

Dr. Reddy's Laboratories has launched Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of ALIMTA (pemetrexed for injection) in the US Market approved by the U.S. Food and Drug Administration (USFDA).

The ALIMTA brand and generic had U.S. sales of approximately $1239 million MAT for the most recent twelve months ending in March 2022 according to IQVIA Health. The company’s Pemetrexed for Injection, is supplied in 100 mg and 500 mg single-dose vials.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Labs. Share Price

1405.80 55.80 (4.13%)
29-Jun-2026 10:54 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1890.30
Dr. Reddys Labs. 1405.80
Cipla 1478.00
Zydus Lifesciences 1120.20
Lupin 2398.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: